Posted by Michael Wonder on 11 Jul 2021
Novartis Korea to continue discussing reimbursement plan for SMA drug Zolgensma
9 July 2021 - Novartis said Friday that it would continue to discuss with the domestic regulators to receive reimbursement for its gene therapy Zolgensma, which has effectively reserved motor developments in infants diagnosed with spinal muscular atrophy.
The company hosted an online conference on Friday and presented an excellent efficacy of its gene therapy and the value it carries for treating rare genetic diseases found in children.
